GSK partners with Bluebird to commercialise gene therapies – Life Sciences Intellectual Property Review (subscription)
|
GSK partners with Bluebird to commercialise gene therapies
Life Sciences Intellectual Property Review (subscription) GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird's lentiviral vector platform. Lentiviral vectors are used as tools for gene delivery in mammalian cells. As part of the agreement, GSK will be given a … |
